» Articles » PMID: 37273749

Disease-related Stigma Among People Who Inject Drugs in Toronto Amidst the COVID-19 Pandemic

Overview
Specialty Psychiatry
Date 2023 Jun 5
PMID 37273749
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Stigma overwhelmingly affects people who inject drugs. The COVID-19 pandemic posed unique challenges for people who inject drugs, who are already stigmatized as being "dangerous and spreading disease." The present study explored ways in which stigma was experienced by a sample of people who inject drugs in Toronto, Canada following COVID-related public health precaution measures.

Methods: Qualitative interviews were conducted with people who inject drugs ( = 24) recruited from supervised consumption sites in Toronto, Canada. The semi-structured interview guide focused on the impact of COVID-19 on participants' health and social well-being. Interviews took place six-months after initial COVID-19 precautions (September-October 2020). We used thematic analysis to examine findings, with stigma being an emergent theme.

Results: Participants described heightened acts of stigma after COVID-19 restrictions were implemented, including feeling treated as "diseased" and the cause of COVID-19's spread. They reported being less likely to receive emergency care during events such as overdoses. Participants perceived increased disease-related stigma evident through actions of stigma, including amplified dehumanization by the public, others avoiding all contact with them, and more discrimination by police and hospital systems.

Conclusion: Participants provided specific examples of how stigmatizing behaviors harmed them after COVID-19 precautions began. It is plausible that stigma contributed to the dramatic increase in fatal overdoses, difficulty accessing housing, and further difficulty accessing needed healthcare in our setting. Integrating evidence-based harm reduction approaches in areas where stigma is evident might offset harms stemming from disease-related stigma and mitigate these harms during future public health emergencies.

Citing Articles

Bridging the Gap in Harm Reduction Using Mobile Overdose Response Services (MORS) in the Context of the COVID-19 Pandemic: A Qualitative Study.

Seo B, Rioux W, Rider N, Teare A, Jones S, Taplay P J Urban Health. 2024; 101(2):252-261.

PMID: 38514599 PMC: 11052954. DOI: 10.1007/s11524-024-00846-y.

References
1.
MacKinnon L, Socias M, Bardwell G . COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings. J Subst Abuse Treat. 2020; 119:108153. PMC: 7532988. DOI: 10.1016/j.jsat.2020.108153. View

2.
Courtwright A . Stigmatization and public health ethics. Bioethics. 2011; 27(2):74-80. DOI: 10.1111/j.1467-8519.2011.01904.x. View

3.
Bardwell G, Fleming T, Collins A, Boyd J, McNeil R . Addressing Intersecting Housing and Overdose Crises in Vancouver, Canada: Opportunities and Challenges from a Tenant-Led Overdose Response Intervention in Single Room Occupancy Hotels. J Urban Health. 2018; 96(1):12-20. PMC: 6391288. DOI: 10.1007/s11524-018-0294-y. View

4.
Marlatt G . Harm reduction: come as you are. Addict Behav. 1996; 21(6):779-88. DOI: 10.1016/0306-4603(96)00042-1. View

5.
Vashishtha D, Mittal M, Werb D . The North American opioid epidemic: current challenges and a call for treatment as prevention. Harm Reduct J. 2017; 14(1):7. PMC: 5427522. DOI: 10.1186/s12954-017-0135-4. View